Eyestem to begin human trials for its pioneering Dry AMD treatment
Dry AMD, a leading cause of vision loss in the ageing population of people over 50, has long been a challenge due to the limited availability of effective treatments and the high costs associated with emerging therapeutic options.
Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.
